Jamroz–Wiśniewska et al. [136] evaluated the level of plasma Hcy, HTL and autoantibodies against N-homocysteine proteins, and PON1 activity in 61 patients with MS, in outbreak-remission (n = 25) and in the secondary-progressive type (n = 36). The gene discussed is PON1; the disease is myeloid sarcoma.